Q1 Earnings Estimate for NKTR Issued By Zacks Research

Nektar Therapeutics (NASDAQ:NKTR) – Zacks Research issued their Q1 2027 earnings per share (EPS) estimates for shares of Nektar Therapeutics in a research report issued on Wednesday, April 2nd. Zacks Research analyst K. Das anticipates that the biopharmaceutical company will post earnings per share of ($0.23) for the quarter. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. Zacks Research also issued estimates for Nektar Therapeutics’ FY2027 earnings at ($1.02) EPS and FY2027 earnings at ($1.02) EPS.

NKTR has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $6.50 price objective on shares of Nektar Therapeutics in a research report on Thursday, March 13th. Oppenheimer upgraded Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a report on Friday, March 14th. B. Riley initiated coverage on shares of Nektar Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $4.00 target price on the stock. Finally, William Blair reaffirmed a “market perform” rating on shares of Nektar Therapeutics in a research report on Thursday, March 13th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Nektar Therapeutics currently has a consensus rating of “Buy” and an average price target of $4.92.

Nektar Therapeutics Stock Down 8.1 %

NASDAQ NKTR opened at $0.55 on Friday. Nektar Therapeutics has a fifty-two week low of $0.53 and a fifty-two week high of $1.93. The business has a fifty day moving average of $0.82 and a 200-day moving average of $1.03. The stock has a market cap of $102.71 million, a price-to-earnings ratio of -0.66 and a beta of 0.65.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Wednesday, March 12th. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.33. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%. The business had revenue of $29.18 million during the quarter, compared to analysts’ expectations of $36.65 million.

Institutional Investors Weigh In On Nektar Therapeutics

Several large investors have recently made changes to their positions in the business. Intech Investment Management LLC acquired a new stake in shares of Nektar Therapeutics during the third quarter valued at about $41,000. The Manufacturers Life Insurance Company acquired a new stake in Nektar Therapeutics in the third quarter valued at $86,000. FMR LLC raised its holdings in Nektar Therapeutics by 403.2% in the third quarter. FMR LLC now owns 386,656 shares of the biopharmaceutical company’s stock valued at $503,000 after acquiring an additional 309,822 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Nektar Therapeutics by 1,877.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 238,846 shares of the biopharmaceutical company’s stock valued at $310,000 after acquiring an additional 226,766 shares during the last quarter. Finally, MetLife Investment Management LLC grew its holdings in Nektar Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 106,506 shares of the biopharmaceutical company’s stock worth $138,000 after acquiring an additional 60,012 shares in the last quarter. Institutional investors and hedge funds own 75.88% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.